Read more
http://news.bms.com/press-release/arthritis/european-commission-approves-bristol-myers-squibbs-orencia-abatacept-treatme
Bristol-Myers Squibb’s
Selected Products list
ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
Prescribing Information including Boxed WARNINGS
Patient Information
Product Website
AZACTAM® (aztreonam injection) in GALAXY Plastic Container
Prescribing Information
AZACTAM® (aztreonam for injection, USP)
Prescribing Information
BARACLUDE® (entecavir)
Prescribing Information including Boxed WARNINGS
Patient Information
Product Website
COUMADIN® (warfarin sodium)
Prescribing Information including Boxed WARNING
Medication Guide
Product Website
DAKLINZA™ (daclatasvir)
Prescribing Information
Patient Information
Product Website
DROXIA® (hydroxyurea)
Prescribing Information including Boxed WARNING
ELIQUIS® (apixaban)
Prescribing Information including Boxed WARNING
Medication Guide
Product Website
EMPLICITI™ (elotuzumab)
Prescribing Information
Patient Information
ETOPOPHOS® (etoposide phosphate)
Prescribing Information including Boxed WARNINGS
EVOTAZ™ (atazanavir and cobicistat)
Prescribing Information
Patient Information
Product Website
GLUCOPHAGE® (metformin hydrochloride)
Prescribing Information
GLUCOPHAGE® XR (metformin hydrochloride) EXTENDED RELEASE
Prescribing Information
GLUCOVANCE® (glyburide and metformin hydrochloride)
Prescribing Information
HYDREA® (hydroxyurea)
Prescribing Information
KENALOG®-10 (triamcinolone acetonide)
Prescribing Information
KENALOG®-40 (triamcinolone acetonide)
Prescribing Information
LYSODREN® (mitotane)
Prescribing Information including Boxed WARNINGS
MEGACE® (megestrol acetate)
Prescribing Information
NULOJIX® (belatacept)
Prescribing Information including Boxed WARNINGS
Medication Guide
REMS Materials
Product Website
OPDIVO® (nivolumab)
Prescribing Information
Medication Guide
Product Website
ORENCIA® (abatacept)
Prescribing Information
Patient Information
Instructions for Use
Product Website
PLAVIX® (clopidogrel bisulfate)
Prescribing Information including Boxed WARNING
Medication Guide
PRAVACHOL® (pravastatin sodium)
Prescribing Information
REYATAZ® (atazanavir)
Prescribing Information
Patient Information
Instructions for Use
Product Website
SPRYCEL® (dasatinib)
Prescribing Information
Patient Information
Product Website
SUSTIVA® (efavirenz)
Prescribing Information
Patient Information
Instructions for Use
SUSTIVA Capsule Instructions for Use Video
Product Website
VIDEX® (didanosine)
Prescribing Information including Boxed WARNINGS
Medication Guide
VIDEX® EC (didanosine) DELAYED RELEASE
Prescribing Information including Boxed WARNINGS
Medication Guide
YERVOY® (ipilimumab)
Prescribing Information including Boxed WARNING
Medication Guide
Product Website
ZERIT® (stavudine)
Prescribing Information including Boxed WARNING
Medication Guide
http://www.bms.com/products/Pages/home.aspx
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Sunday, October 9, 2016, at 7:30 p.m. CEST (1:30 p.m. EDT) to discuss data presented at the European Society of Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark. Company executives will provide an overview of data presented at the meeting, with a focus on the company’s Immuno-Oncology portfolio, and address inquiries from investors and analysts.
http://news.bms.com/press-release/financial-news/bristol-myers-squibb-hold-investor-teleconference-discuss-esmo-2016-con
Link to listen
http://investors.bms.com/investors/news-and-events/events-and-presentations/event-details/2016/ESMO-Investor-Event-2016/default.aspx
1c
Recent BMY News
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial • Business Wire • 05/10/2024 08:30:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 10:59:00 AM
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/06/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... • Business Wire • 05/06/2024 10:59:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM